FGFR2 and biliary tract cancer: For example, in the BITCOIN trial (17), out of 286 biliary tract cancer cases analyzed, the 24 patients (8.4%) with FGFR2/3 alteration had a better OS compared to FGFR wild-type cases (29.2 vs 14.4 months, p = 0.003).